Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Fell

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
JCO Precision Oncology|September 11, 2020
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With GlioblastomaBrian M Alexander, Lorenzo Trippa, Sarah Gaffey, et al.
Blood|November 5, 2025
Multinational Assessment of Absolute Neutrophil Counts and White Blood Cell Counts Among Healthy Duffy Null AdultsStephen P Hibbs, Israel Chipare, Amr J Halawani, et al.
Science Translational Medicine|September 6, 2023
Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomasPierpaolo Peruzzi, Christine Dominas, Geoffrey Fell, et al.
Blood Advances|January 10, 2024
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AMLJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemiaEmma-Jayne Minihane, Leah Krotee, Jason Wu, et al.
Blood Advances|October 6, 2021
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and activeJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Leukemia & Lymphoma|March 12, 2025
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adultsPhilip C Amrein, Frederic I Preffer, Geoffrey Fell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2019
Progression Risk Stratification of Asymptomatic Waldenström MacroglobulinemiaMark Bustoros, Romanos Sklavenitis-Pistofidis, Prashant Kapoor, et al.
Blood Advances|December 5, 2025
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AMLJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Blood Cancer Discovery|December 5, 2022
In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic VulnerabilitiesElisa Ten Hacken, Tomasz Sewastianik, Shanye Yin, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
JCO Precision Oncology|September 11, 2020
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With GlioblastomaBrian M Alexander, Lorenzo Trippa, Sarah Gaffey, et al.
Blood|November 5, 2025
Multinational Assessment of Absolute Neutrophil Counts and White Blood Cell Counts Among Healthy Duffy Null AdultsStephen P Hibbs, Israel Chipare, Amr J Halawani, et al.
Science Translational Medicine|September 6, 2023
Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomasPierpaolo Peruzzi, Christine Dominas, Geoffrey Fell, et al.
Blood Advances|January 10, 2024
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AMLJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemiaEmma-Jayne Minihane, Leah Krotee, Jason Wu, et al.
Blood Advances|October 6, 2021
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and activeJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Leukemia & Lymphoma|March 12, 2025
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adultsPhilip C Amrein, Frederic I Preffer, Geoffrey Fell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2019
Progression Risk Stratification of Asymptomatic Waldenström MacroglobulinemiaMark Bustoros, Romanos Sklavenitis-Pistofidis, Prashant Kapoor, et al.
Blood Advances|December 5, 2025
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AMLJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Blood Cancer Discovery|December 5, 2022
In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic VulnerabilitiesElisa Ten Hacken, Tomasz Sewastianik, Shanye Yin, et al.
Pageof 5